ALLYRNA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ALLYRNA - overview
Established
2025
Location
Hong Kong, -, Hong Kong SAR - China
Primary Industry
Pharmaceuticals
About
Founded in 2025 and based in Hong Kong, China, ALLYRNA was established by Professor He Chuan of the University of Chicago, an expert in RNA epigenetics and recipient of the Wolf Prize in Chemistry. The company’s development strategy centers on drug innovation, aiming to address unmet needs in cancer treatment. ALLYRNA is building a technology platform focused on sensitizers for radiotherapy and immunotherapy. The company's pipeline emphasizes first-in-class small molecule drugs that enhance therapeutic responses in oncology, with applications in tumor treatment and potentially other related disease areas.
As a research-driven biotechnology company, ALLYRNA is currently in the development stage. Future revenue is expected to derive from licensing of intellectual property, partnerships with pharmaceutical companies, and eventual commercialization of its proprietary drug candidates. In August 2025, ALLYRNA raised nearly USD 10 million in seed funding, co led by 3 new investors Jifeng Ventures, Gaorong Ventures and Together To Miracle Capital, with participation from new investor Plaisance Capital.
Current Investors
Plaisance Capital, Gaorong Ventures, Jifeng Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Biotechnology, Healthcare, Pharmaceuticals
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.